[Changes of amino acids neurotransmitters in striatum of hemi-parkinsonian rhesus monkey after high frequency stimulation of subthalamic nucleus].
OBJECTIVE
To investigate the influence of high frequency stimulation of the subthalamic nucleus on the levels of amino acids neurotransmitters in striatum of hemi-parkinsonian monkeys.


METHODS
Two rhesus monkeys were successfully prepared for the subsequent microdialysis sessions. Collecting the dialysate before turning on the pulse generator, and collecting at 1 week, 1, 8 and 12 months after high frequency stimulation of the subthalamic nucleus. The level of Glu, GABA and Tau were determined by high performance liquid chromatography and fluorometric detection (HPLC-FD).


RESULTS
After high frequency stimulation (HFS), PD symptoms of monkeys significantly improved. The levels of Glu in putamen and caudate nucleus of electrodes side at 1 week, 1, 8 and 12 months were increased significantly. The levels of GABA in putamen and caudate nucleus of electrodes side at 1 week, 1 month increased significantly compared with before turning on the pulse generator while decreased at 8, 12 months. The level of Tau in putamen and caudate nucleus increased significantly.


CONCLUSIONS
Long-term STN HFS can increase the level of glutamate and taurine, while decrease the level of GABA in putamen and caudate nucleus of electrodes side. It improves symptoms of hemi-parkinsonian rhesus monkey significantly.
Zhao
Xu-Dong
XD
Department of Neurosurgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
Zhou
Xiao-Ping
XP
Liu
Han-Hua
HH
Li
Bao-Ming
BM
Hu
Xiao-Wu
XW
Li
Feng-Qian
FQ
You
Ben-Ming
BM
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000596:Amino Acids / Q000378:metabolism*; D000818:Animals; D002851:Chromatography, High Pressure Liquid; D003342:Corpus Striatum / Q000378:metabolism*; D046690:Deep Brain Stimulation / Q000379:methods*; D004195:Disease Models, Animal; D018698:Glutamic Acid / Q000378:metabolism; D008253:Macaca mulatta; D017551:Microdialysis; D009498:Neurotoxins / Q000633:toxicity; D018377:Neurotransmitter Agents / Q000378:metabolism*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000378:metabolism / Q000628:therapy*; D020531:Subthalamic Nucleus; D013654:Taurine / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D000596:Amino Acids; D009498:Neurotoxins; D018377:Neurotransmitter Agents; D013654:Taurine; D018698:Glutamic Acid; D005680:gamma-Aminobutyric Acid; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine